2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The objective of this study is to deliver the *proof-of-concept* that locally administered pilocarpine drops are effective in a population of elderly with xerostomia at expense of a minimum of side effects.